Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- 2021 Insights into the Global Cystic Fibrosis Clinical Trial Pipeline - ResearchAndMarkets.comon January 20, 2021 at 10:03 pm
The “Global Cystic Fibrosis Clinical Trial Pipeline Highlights - 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline ...
- Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical ...on January 20, 2021 at 9:54 pm
(GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and ...
- 'Miracle' drug transforms life of young woman with cystic fibrosison January 19, 2021 at 9:00 pm
Isobel Richards previously struggled to walk up the stairs without taking a break but says her life has now 'completely changed' ...
- Family of Ontario brothers with Cystic Fibrosis fight for province’s help to access vital drugson January 19, 2021 at 3:59 pm
Family of Ontario brothers with Cystic Fibrosis fight to fast track life-saving drug For Canadians with Cystic Fibrosis (CF), there may be a tiny silver lining to the COVID-19 pandemic. “All of the ...
- Family of Ontario brothers with Cystic Fibrosis fight to fast track life-saving drugon January 19, 2021 at 2:45 pm
Watch Family of Ontario brothers with Cystic Fibrosis fight to fast track life-saving drug Video Online, on GlobalNews.ca ...
- Cystic Fibrosis Market Overview By Share, Size, Industry Players, Revenue and Product Demandon January 19, 2021 at 8:32 am
Cystic Fibrosis Market Prospects & Upcoming Trends and Opportunities Analyzed for Coming Years "The report on the global cystic fibrosis (CF) market provides qualitative and quantitative analysis for ...
- Drag star uses shows to raise awareness of cystic fibrosison January 14, 2021 at 3:45 am
Jordan McKinley may have cystic fibrosis but, as a teenager, discovered a love of drag and became artist Jordy Deelight. Despite spending years in and out of hospital, Jordy has not let their ...
- Cystic Fibrosis Market Size, Revenue, Demand, Shares, Analysis and Forecasts to 2025on January 13, 2021 at 10:37 am
Information By Treatment Method (Medication, Devices, Others) and By Region (North America, Europe, Asia-Pacific and the Middle East & Africa) – Forecast till 2025 According to a recent study report ...
- Medicare Coverage for Cystic Fibrosis: Testing, Management, and Treatmentson January 12, 2021 at 1:31 pm
Medicare covers the testing, treatment, and care you need for cystic fibrosis. Find out exactly what's covered by the different parts of Medicare.
- Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugson January 11, 2021 at 8:40 am
With its balance sheet growing with cash from its cystic fibrosis drugs, Vertex has the “financial firepower” to consider deals, CEO says.
via Bing News